Literature DB >> 20580090

Complement control protein factor H: the good, the bad, and the inadequate.

Viviana P Ferreira1, Michael K Pangburn, Claudio Cortés.   

Abstract

The complement system is an essential component of the innate immune system that participates in elimination of pathogens and altered host cells and comprises an essential link between the innate and adaptive immune system. Soluble and membrane-bound complement regulators protect cells and tissues from unintended complement-mediated injury. Complement factor H is a soluble complement regulator essential for controlling the alternative pathway in blood and on cell surfaces. Normal recognition of self-cell markers (i.e. polyanions) and C3b/C3d fragments is necessary for factor H function. Inadequate recognition of host cell surfaces by factor H due to mutations and polymorphisms have been associated with complement-mediated tissue damage and disease. On the other hand, unwanted recognition of pathogens and altered self-cells (i.e. cancer) by factor H is used as an immune evasion strategy. This review will focus on the current knowledge related to these versatile recognition properties of factor H. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20580090      PMCID： PMC2921957          DOI： 10.1016/j.molimm.2010.05.007

Source DB:  PubMed          Journal:  Mol Immunol        ISSN： 0161-5890            Impact factor:   4.407


  219 in total

1.  Complement factor H gene mutation associated with autosomal recessive atypical hemolytic uremic syndrome.

Authors:  M R Buddles; R L Donne; A Richards; J Goodship; T H Goodship
Journal:  Am J Hum Genet       Date:  2000-05       Impact factor: 11.025

2.  Each of the three binding sites on complement factor H interacts with a distinct site on C3b.

Authors:  T S Jokiranta; J Hellwage; V Koistinen; P F Zipfel; S Meri
Journal:  J Biol Chem       Date:  2000-09-08       Impact factor: 5.157

3.  Exceptional resistance of human H2 glioblastoma cells to complement-mediated killing by expression and utilization of factor H and factor H-like protein 1.

Authors:  S Junnikkala; T S Jokiranta; M A Friese; H Jarva; P F Zipfel; S Meri
Journal:  J Immunol       Date:  2000-06-01       Impact factor: 5.422

4.  Molecular mechanisms of target recognition in an innate immune system: interactions among factor H, C3b, and target in the alternative pathway of human complement.

Authors:  M K Pangburn; K L Pangburn; V Koistinen; S Meri; A K Sharma
Journal:  J Immunol       Date:  2000-05-01       Impact factor: 5.422

Review 5.  Factor H and the pathogenesis of renal diseases.

Authors:  B H Ault
Journal:  Pediatr Nephrol       Date:  2000-09       Impact factor: 3.714

6.  Human complement proteins C3b, C4b, factor H and properdin react with specific sites in gp120 and gp41, the envelope proteins of HIV-1.

Authors:  H Stoiber; R Schneider; J Janatova; M P Dierich
Journal:  Immunobiology       Date:  1995-06       Impact factor: 3.144

7.  Direct interaction of complement factor H with the C1 domain of HIV type 1 glycoprotein 120.

Authors:  C Pintér; A G Siccardi; R Longhi; A Clivio
Journal:  AIDS Res Hum Retroviruses       Date:  1995-05       Impact factor: 2.205

8.  Tyrosine is a potential site for covalent attachment of activated complement component C3.

Authors:  A Sahu; M K Pangburn
Journal:  Mol Immunol       Date:  1995-07       Impact factor: 4.407

9.  HIV glycoprotein 41 and complement factor H interact with each other and share functional as well as antigenic homology.

Authors:  C Pintér; A G Siccardi; L Lopalco; R Longhi; A Clivio
Journal:  AIDS Res Hum Retroviruses       Date:  1995-08       Impact factor: 2.205

10.  Mapping of the complement regulatory domains in the human factor H-like protein 1 and in factor H1.

Authors:  S Kühn; C Skerka; P F Zipfel
Journal:  J Immunol       Date:  1995-12-15       Impact factor: 5.422
View more
  141 in total

Review 1.  Dynamic control of the complement system by modulated expression of regulatory proteins.

Authors:  Joshua M Thurman; Brandon Renner
Journal:  Lab Invest       Date:  2010-10-04       Impact factor: 5.662

2.  Sialic acid on the neuronal glycocalyx prevents complement C1 binding and complement receptor-3-mediated removal by microglia.

Authors:  Bettina Linnartz; Jens Kopatz; Andrea J Tenner; Harald Neumann
Journal:  J Neurosci       Date:  2012-01-18       Impact factor: 6.167

3.  The relative roles of factor H binding protein, neisserial surface protein A, and lipooligosaccharide sialylation in regulation of the alternative pathway of complement on meningococci.

Authors:  Lisa A Lewis; Matthew Carter; Sanjay Ram
Journal:  J Immunol       Date:  2012-04-13       Impact factor: 5.422

Review 4.  Complement activation, regulation, and molecular basis for complement-related diseases.

Authors:  Goran Bajic; Søren E Degn; Steffen Thiel; Gregers R Andersen
Journal:  EMBO J       Date:  2015-10-21       Impact factor: 11.598

5.  Inhibition of the alternative pathway of nonhuman infant complement by porin B2 contributes to virulence of Neisseria meningitidis in the infant rat model.

Authors:  Lisa A Lewis; David M Vu; Dan M Granoff; Sanjay Ram
Journal:  Infect Immun       Date:  2014-03-31       Impact factor: 3.441

6.  Factor H-IgG Chimeric Proteins as a Therapeutic Approach against the Gram-Positive Bacterial Pathogen Streptococcus pyogenes.

Authors:  Anna M Blom; Michal Magda; Lisa Kohl; Jutamas Shaughnessy; John D Lambris; Sanjay Ram; David Ermert
Journal:  J Immunol       Date:  2017-10-30       Impact factor: 5.422

Review 7.  Hemolytic uremic syndrome.

Authors:  Caterina Mele; Giuseppe Remuzzi; Marina Noris
Journal:  Semin Immunopathol       Date:  2014-02-14       Impact factor: 9.623

8.  Analysis of the complement sensitivity of oral treponemes and the potential influence of FH binding, FH cleavage and dentilisin activity on the pathogenesis of periodontal disease.

Authors:  D P Miller; J V McDowell; J K Bell; M P Goetting-Minesky; J C Fenno; R T Marconi
Journal:  Mol Oral Microbiol       Date:  2014-06-03       Impact factor: 3.563

9.  Complement-Regulatory Proteins CFHR1 and CFHR3 and Patient Response to Anti-CD20 Monoclonal Antibody Therapy.

Authors:  Laura M Rogers; Sarah L Mott; Brian J Smith; Brian K Link; Deniz Sahin; George J Weiner
Journal:  Clin Cancer Res       Date:  2016-08-15       Impact factor: 12.531

Review 10.  The Neuro-Immune-Regulators (NIREGs) Promote Tissue Resilience; a Vital Component of the Host's Defense Strategy against Neuroinflammation.

Authors:  Yosra Bedoui; Jim W Neal; Philippe Gasque
Journal:  J Neuroimmune Pharmacol       Date:  2018-06-16       Impact factor: 4.147
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.